ImmunityBio, Inc. IBRX

$IBRX Bought 22,000 shares of IBRX on 4/25 at an average price of $4.97. Plan to hold for 3-5 years aiming for a 500% profit and retirement. (1)Anktiva avoid 90% of cystectomy in bladder cancer and has applied for inclusion in the NCCN guidelines (2)Received FDA approval on 4/22/24 and will be available for sale on 5/6/24 (3)Expected to treat 20,000 patients annually (4)Treatment regimen consists of 36 doses over 37 months, priced at $35,800 per dose (5)Estimated annual revenue potential of $8.5 billion for bladder cancer treatment in the US, with current market cap at only $5 billion (6)Rapid FDA submissions have been made in Canada, the UK, Germany, France, Spain, and Italy. Potential strategic partners are approaching IBRX (7)Phase 3 clinical trial underway for BCG-naive bladder cancer patients (8)Lung cancer clinical trial has shown a doubling of survival time from 7-8 months to 14-18 months (9)Lung cancer trial data submitted for publication, while bladder cancer trial results have been published in the prestigious NEJM (10)Clinical trials ongoing for lung cancer, colon cancer, ovarian cancer, Lynch syndrome, and HIV. (11)Attending the AUA conference from May 3-6, 2024, and the ASCO conference from May 31 to June 4, 2024. Scheduled meeting with FDA in June to discuss lung indication application (12)Earnings call scheduled for July!!!

$IBRX Bought 22K shares avg 4.97 on 4/25. Not going to sell any single share !! l'm going to hold Iong so I can retire shortly !!! Don't take 50% profit instead of 500%. 80K new diagnosis bladder CA a year in US. 75% are NMIBC, and 30% of them are not responsive to BCG. Which mean 20K patients are indicated for ANKTIVA. 36 doses in 37 weeks with 35800 per dose. 20K 3635800 = 25B.... Why would you sell a 5b market cap stock that can earn 25b a year?

$IBRX Bought 22K shares avg 4.97 on 4/25. Not going to sell any single share !!! I'm going to hold long so I can retire shortly !!! Don't take 50% profit instead of 500%. 80K new diagnosis bladder CA a year in US. 75% are NMIBC, and 30% of them are not responsive to BCG. Which mean 20K patients are indicated for ANKTIVA. 36 doses in 37 weeks with 35800 per dose. 20K 3635800 = 25B.... Why would you sell a 5b market cap stock that can earn 25b a year?

$IBRX 83000 new diagnosis of bladder cancer per year in US. 75% are NMIBC. 30-50% of NMIBC failed to BCG. Which mean around 18-30K person are indicated for Anktiva. (Just google it) Let's use 18K for math. 1800038500/dose12 months=8,316,000,000 = 8 billions. Now the stock priced 5 billions....while they can easily earn 8 billions a year. That only counts bladder cancer in US....what If we include Europe and Asia? What if we get indication for lung cancer? Do the math and buy the stock !!!

$IBRX it's just the beginning. Bought 22K shares at 4.97 yesterday and 24K shares at 7.32. It will reach 40 per shares when we get indication for Lung CA.

$IBRX MERK will buy us at anytime if PSS agree.

$IBRX it's only the beginning, won't sell it until double digits !!! Hold it and burn shorts!!!

$IBRX double digits AH

$IBRX burn the shorts !!! Hold it long until 20 per share!!!

$IBRX IMO, 10 per share after market